Cidara Therapeutics Inc. (CDTX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Cidara Therapeutics Inc. faces a significant business risk due to its delayed Form 10-K filing with the SEC for the fiscal year ending December 31, 2023. This delay renders the company ineligible to utilize Form S-3 for registering securities, which is a streamlined process for capital raising and conducting acquisitions. The inability to promptly file all required periodic reports may lead to higher transaction costs and extended timelines for future securities offerings. Consequently, this impediment could adversely impact Cidara’s strategic initiatives and financial stability.
The average CDTX stock price target is $15.50, implying 29.17% upside potential.
To learn more about Cidara Therapeutics Inc.’s risk factors, click here.
